Point-of-Care Molecular Diagnostics Market (By Technology: PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based; By Application: Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other; By Location: OTC, POC; By End Use: Decentralized Labs, Hospitals, Homecare, Assisted Living Healthcare Facilities, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Point-of-Care Molecular Diagnostics Market
5.1. COVID-19 Landscape: Point-of-Care Molecular Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Point-of-Care Molecular Diagnostics Market, By Technology
8.1. Point-of-Care Molecular Diagnostics Market, by Technology, 2023-2032
8.1.1. PCR-based
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Genetic Sequencing-based
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Hybridization-based
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Microarray-based
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Point-of-Care Molecular Diagnostics Market, By Application
9.1. Point-of-Care Molecular Diagnostics Market, by Application, 2023-2032
9.1.1. Infectious Diseases
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Hematology
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Prenatal Testing
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Endocrinology
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Other
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Point-of-Care Molecular Diagnostics Market, By Location
10.1. Point-of-Care Molecular Diagnostics Market, by Location, 2023-2032
10.1.1. OTC
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. POC
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Point-of-Care Molecular Diagnostics Market, By End Use
11.1. Point-of-Care Molecular Diagnostics Market, by End Use, 2023-2032
11.1.1. Decentralized Labs
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Homecare
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Assisted Living Healthcare Facilities
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Point-of-Care Molecular Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Location (2020-2032)
12.1.4. Market Revenue and Forecast, by End Use (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Location (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End Use (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Location (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End Use (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Location (2020-2032)
12.2.4. Market Revenue and Forecast, by End Use (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Location (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End Use (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Location (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End Use (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Location (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End Use (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Location (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End Use (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Location (2020-2032)
12.3.4. Market Revenue and Forecast, by End Use (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Location (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End Use (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Location (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End Use (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Location (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End Use (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Location (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End Use (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Location (2020-2032)
12.4.4. Market Revenue and Forecast, by End Use (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Location (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End Use (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Location (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End Use (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Location (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End Use (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Location (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End Use (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Location (2020-2032)
12.5.4. Market Revenue and Forecast, by End Use (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Location (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End Use (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Location (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End Use (2020-2032)
Chapter 13. Company Profiles
13.1. Abbott Laboratories, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Roche Diagnostics
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. bioMérieux SA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Danaher Corporation (Beckman Coulter)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cepheid (a subsidiary of Danaher Corporation)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN N.V.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Thermo Fisher Scientific, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Hologic, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bio-Rad Laboratories, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Becton, Dickinson and Company (BD)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client